A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals.

All over the world, diarrhoea is one of the major causes of morbidity and mortality in calves. Prospective studies of diarrhoea point out an incidence of 20 or even 55 cases per 100 calves. A mortality rate for diarrhoea of 1/ 20 is usually considered in Europe. Actually, treatment of diarrhoea by fluidtherapy only focuses on correction of hydric, electrolytic, acido basic and energetic disorders. However, it has been demonstrated that oxygen transport by the blood and oxygen extraction at the tissue level was also impaired in diarrhoeic calves (Cambier et al, American Journal of Veterinary Research, 2001) and that classical treatments are unable to correct (and may even worsen) these impairments of oxygen extraction (Cambier et al., in press). In this context, the present invention relates to a new veterinary medicinal composition designed in order to maintain the oxygenic consumption by : - an increase in oxygen extraction at the tissue level - an increase in cardiac output The new medicinal composition is also designed to restore hydric, electrolytic and energetic status in affected mammals, as well as the blood pH, in a range which is compatible with the blood oxygen transport The potential applications are the treatment of diseases associated with tissue hypoxia in mammals, particularly diarrhoea and endotoxaemic shock in bovine

Phase III/IV

patent under prosecution in EP, CA, US.

Research collaboration for license agreement